




RealRate

PHARMACEUTICAL 2017

Clovis Oncology Inc.
Rank 219 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Clovis Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Clovis Oncology Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 87% points. The greatest weakness of Clovis Oncology Inc. is the variable Net Income, reducing the Economic Capital Ratio by 141% points.

The company's Economic Capital Ratio, given in the ranking table, is -388%, being 28% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	279,410
Cost of Goods Sold	0
Intangible Assets	78,239
Liabilities, Current	65,597
Liabilities, Non-Current	0
Other Assets	2,468
Other Compr. Net Income	-120
Other Expenses	47,617
Other Liabilities	302,594
Other Net Income	-8,438
Property and Equipment	4,440
Research and Development	252,429
Revenues	78
Selling, General and Administrative Expense	40,731

Output Variable	Value in 1000 USD
Assets	364,557
Liabilities	368,191
Expenses	340,777
Stockholders Equity	-3,634
Net Income	-349,137
Comprehensive Net Income	-349,197
Economic Capital Ratio	-388%